CNS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1996 USD | -3.90% |
|
-16.83% | -84.28% |
| Apr. 30 | Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call | |
| Apr. 23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call |
Presenter SpeechJenene Thomas (Attendees)Okay. We're ready to start. Good morning, everyone, a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -84.28% | 2.12M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.24% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- CNSP Stock
- News CNS Pharmaceuticals, Inc.
- Transcript : CNS Pharmaceuticals, Inc. - Special Call